A Tetraspecific VHH-Based Neutralizing Antibody Modifies Disease Outcome in Three Animal Models of Clostridium difficile Infection

ABSTRACT Clostridium difficile infection (CDI), a leading cause of nosocomial infection, is a serious disease in North America, Europe, and Asia. CDI varies greatly from asymptomatic carriage to life-threatening diarrhea, toxic megacolon, and toxemia. The incidence of community-acquired infection has increased due to the emergence of hypervirulent antibiotic-resistant strains. These new strains contribute to the frequent occurrence of disease relapse, complicating treatment, increasing hospital stays, and increasing morbidity and mortality among patients. Therefore, it is critical to develop new therapeutic approaches that bypass the development of antimicrobial resistance and avoid disruption of gut microflora. Here, we describe the construction of a single heteromultimeric VHH-based neutralizing agent (VNA) that targets the two primary virulence factors of Clostridium difficile, toxins A (TcdA) and B (TcdB). Designated VNA2-Tcd, this agent has subnanomolar toxin neutralization potencies for both C. difficile toxins in cell assays. When given systemically by parenteral administration, VNA2-Tcd protected against CDI in gnotobiotic piglets and mice and to a lesser extent in hamsters. Protection from CDI was also observed in gnotobiotic piglets treated by gene therapy with an adenovirus that promoted the expression of VNA2-Tcd.

[1]  J. Bartlett,et al.  The new Clostridium difficile--what does it mean? , 2005, The New England journal of medicine.

[2]  G. Douce,et al.  Infection of hamsters with the UK Clostridium difficile ribotype 027 outbreak strain R20291 , 2011, Journal of medical microbiology.

[3]  S. Coffin,et al.  Epidemiological Features of Clostridium difficile-Associated Disease Among Inpatients at Children's Hospitals in the United States, 2001–2006 , 2008, Pediatrics.

[4]  L. Wyns,et al.  Selection and identification of single domain antibody fragments from camel heavy‐chain antibodies , 1997, FEBS letters.

[5]  J. Maizel,et al.  The polypeptides of adenovirus. I. Evidence for multiple protein components in the virion and a comparison of types 2, 7A, and 12. , 1974, Virology.

[6]  M. Kolber,et al.  Probiotics for the prevention of Clostridium difficile. , 2013, Canadian family physician Medecin de famille canadien.

[7]  M. Abougergi,et al.  Intravenous Immunoglobulin for the Treatment of Clostridium difficile Infection: A Review , 2010, Digestive Diseases and Sciences.

[8]  R. Durai.  Epidemiology, Pathogenesis, and Management of Clostridium difficile Infection , 2007, Digestive Diseases and Sciences.

[9]  T. Wilkins,et al.  Clostridium difficile: its disease and toxins , 1988, Clinical Microbiology Reviews.

[10]  S. Tzipori,et al.  Systemically Administered IgG Anti-Toxin Antibodies Protect the Colonic Mucosa during Infection with Clostridium difficile in the Piglet Model , 2014, PloS one.

[11]  D. Gerding,et al.  Breakthroughs in the treatment and prevention of Clostridium difficile infection , 2016, Nature Reviews Gastroenterology &Hepatology.

[12]  C. Woods,et al.  Comparison of Seven Techniques for Typing International Epidemic Strains of Clostridium difficile: Restriction Endonuclease Analysis, Pulsed-Field Gel Electrophoresis, PCR-Ribotyping, Multilocus Sequence Typing, Multilocus Variable-Number Tandem-Repeat Analysis, Amplified Fragment Length Polymorphis , 2007, Journal of Clinical Microbiology.

[13]  K. Kinzler,et al.  A protocol for rapid generation of recombinant adenoviruses using the AdEasy system , 2007, Nature Protocols.

[14]  Roger Baxter,et al.  Treatment with monoclonal antibodies against Clostridium difficile toxins. , 2010, The New England journal of medicine.

[15]  Julian I. Rood,et al.  Toxin B is essential for virulence of Clostridium difficile , 2009, Nature.

[16]  Duolao Wang,et al.  A high-dose preparation of lactobacilli and bifidobacteria in the prevention of antibiotic-associated and Clostridium difficile diarrhoea in older people admitted to hospital: a multicentre, randomised, double-blind, placebo-controlled, parallel arm trial (PLACIDE). , 2013, Health technology assessment.

[17]  S. Tzipori,et al.  Piglet models of acute or chronic Clostridium difficile illness. , 2010, The Journal of infectious diseases.

[18]  D. Goulding,et al.  Refinement of the hamster model of Clostridium difficile disease. , 2010, Methods in molecular biology.

[19]  S. Tzipori,et al.  Systemic dissemination of Clostridium difficile toxins A and B is associated with severe, fatal disease in animal models. , 2012, The Journal of infectious diseases.

[20]  F. Barbut,et al.  Epidemiology of Recurrences or Reinfections ofClostridium difficile-Associated Diarrhea , 2000, Journal of Clinical Microbiology.

[21]  A. Sambanis,et al.  Proteasome modulating agents induce rAAV2-mediated transgene expression in human intestinal epithelial cells. , 2005, Biochemical and biophysical research communications.

[22]  Min Zhang,et al.  The pharmacokinetics of an albumin-binding Fab (AB.Fab) can be modulated as a function of affinity for albumin. , 2006, Protein engineering, design & selection : PEDS.

[23]  P. Whiting,et al.  Systematic review and meta-analysis of the current evidence on the duration of protection by bacillus Calmette-Guérin vaccination against tuberculosis. , 2013, Health technology assessment.

[24]  R. Seaton,et al.  Faecal transplant for recurrent Clostridium difficile-associated diarrhoea: a UK case series. , 2009, QJM : monthly journal of the Association of Physicians.

[25]  N. Mantis,et al.  Mechanisms of Ricin Toxin Neutralization Revealed through Engineered Homodimeric and Heterodimeric Camelid Antibodies* , 2015, The Journal of Biological Chemistry.

[26]  N. Minton,et al.  University of Birmingham Importance of Toxin A, Toxin B, and CDT in virulence of an epidemic Clostridium difficile strain , 2013 .

[27]  C. Seifert,et al.  Effect of treatment variation on outcomes in patients with Clostridium difficile. , 2014, The American journal of medicine.

[28]  K. Tateda,et al.  Evidence of intravenous immunoglobulin as a critical supportive therapy against Clostridium difficile toxin-mediated lethality in mice. , 2011, The Journal of antimicrobial chemotherapy.

[29]  M. P. Bauer,et al.  The Changing Epidemiology of Clostridium difficile Infections , 2010, Clinical Microbiology Reviews.

[30]  S. Leppla,et al.  Adenoviral Expression of a Bispecific VHH-Based Neutralizing Agent That Targets Protective Antigen Provides Prophylactic Protection from Anthrax in Mice , 2016, Clinical and Vaccine Immunology.

[31]  N. Mantis,et al.  Stepwise Engineering of Heterodimeric Single Domain Camelid VHH Antibodies That Passively Protect Mice from Ricin Toxin* , 2013, The Journal of Biological Chemistry.

[32]  Melinda B Davis,et al.  A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea, stratified by disease severity. , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[33]  L. Scott.  Fidaxomicin: A Review of Its Use in Patients with Clostridium difficile Infection , 2013, Drugs.

[34]  C T Verrips,et al.  Comparison of physical chemical properties of llama VHH antibody fragments and mouse monoclonal antibodies. , 1999, Biochimica et biophysica acta.

[35]  K. K. Andersen,et al.  Neutralization of Clostridium difficile Toxin B Mediated by Engineered Lactobacilli That Produce Single-Domain Antibodies , 2015, Infection and Immunity.

[36]  B. Currie,et al.  Impact of adding prophylactic probiotics to a bundle of standard preventative measures for Clostridium difficile infections: enhanced and sustained decrease in the incidence and severity of infection at a community hospital , 2013, Current medical research and opinion.

[37]  T. Monath,et al.  Clostridium difficile toxoid vaccine in recurrent C. difficile-associated diarrhea. , 2005, Gastroenterology.

[38]  Michael B Gravenor,et al.  Lactobacilli and bifidobacteria in the prevention of antibiotic-associated diarrhoea and Clostridium difficile diarrhoea in older inpatients (PLACIDE): a randomised, double-blind, placebo-controlled, multicentre trial , 2013, The Lancet.

[39]  G. Armstrong,et al.  Therapeutic potential of egg yolk antibodies for treating Clostridium difficile infection. , 2011, Journal of medical microbiology.

[40]  C. Surawicz,et al.  Alteration of the intestinal microbiome: fecal microbiota transplant and probiotics for Clostridium difficile and beyond , 2013, Expert review of gastroenterology & hepatology.

[41]  S. Tzipori,et al.  Adenovirus Vector Expressing Stx1/Stx2-Neutralizing Agent Protects Piglets Infected with Escherichia coli O157:H7 against Fatal Systemic Intoxication , 2014, Infection and Immunity.

[42]  G. Oyler,et al.  Camelid single domain antibodies (VHHs) as neuronal cell intrabody binding agents and inhibitors of Clostridium botulinum neurotoxin (BoNT) proteases. , 2010, Toxicon : official journal of the International Society on Toxinology.

[43]  Patrick M. Wright,et al.  A Novel Strategy for Development of Recombinant Antitoxin Therapeutics Tested in a Mouse Botulism Model , 2012, PloS one.

[44]  Rebecca E. Sohn,et al.  The myeloid binding peptide adenoviral vector enables multi-organ vascular endothelial gene targeting , 2014, Laboratory Investigation.

[45]  S. Tzipori,et al.  Hyperimmune bovine colostrum as a novel therapy to combat Clostridium difficile infection. , 2014, The Journal of infectious diseases.

[46]  S. Leppla,et al.  A Heterodimer of a VHH (Variable Domains of Camelid Heavy Chain-only) Antibody That Inhibits Anthrax Toxin Cell Binding Linked to a VHH Antibody That Blocks Oligomer Formation Is Highly Protective in an Anthrax Spore Challenge Model* , 2015, The Journal of Biological Chemistry.

[47]  H. Pituch.  Clostridium difficile is no longer just a nosocomial infection or an infection of adults. , 2009, International journal of antimicrobial agents.

[48]  V. Young,et al.  Overlapping roles for toxins in Clostridium difficile infection. , 2014, The Journal of infectious diseases.

[49]  F. Gunzer,et al.  The role of the eaeA gene in diarrhea and neurological complications in a gnotobiotic piglet model of enterohemorrhagic Escherichia coli infection , 1995, Infection and immunity.

[50]  P. Giannasca,et al.  Active and passive immunization against Clostridium difficile diarrhea and colitis. , 2004, Vaccine.

[51]  D. Curiel,et al.  Prolonged Prophylactic Protection from Botulism with a Single Adenovirus Treatment Promoting Serum Expression of a VHH-Based Antitoxin Protein , 2014, PloS one.

[52]  B. E. Kimmel,et al.  Neutralization of Clostridium difficile toxin A using antibody combinations , 2010, mAbs.

[53]  N. Minton,et al.  Both, toxin A and toxin B, are important in Clostridium difficile infection. , 2011, Gut microbes.

[54]  S. Calderwood,et al.  Transcutaneous Immunization with Clostridium difficile Toxoid A Induces Systemic and Mucosal Immune Responses and Toxin A-Neutralizing Antibodies in Mice , 2007, Infection and Immunity.

[55]  R. Barker,et al.  GT160-246, a Toxin Binding Polymer for Treatment ofClostridium difficile Colitis , 2001, Antimicrobial Agents and Chemotherapy.

[56]  S. Tzipori,et al.  A Single VHH-Based Toxin-Neutralizing Agent and an Effector Antibody Protect Mice against Challenge with Shiga Toxins 1 and 2 , 2013, Infection and Immunity.

[57]  C. Gessert,et al.  STOOL TRANSPLANTATION FOR OLDER PATIENTS WITH CLOSTRIDIUM DIFFICILE INFECTION , 2009, Journal of the American Geriatrics Society.

[58]  J. Kleijnen,et al.  Rapid fetal fibronectin testing to predict preterm birth in women with symptoms of premature labour: a systematic review and cost analysis. , 2013, Health technology assessment.

[59]  L. Wyns,et al.  Single‐domain antibody fragments with high conformational stability , 2002, Protein science : a publication of the Protein Society.

[60]  A. Therien,et al.  Mechanisms of Protection against Clostridium difficile Infection by the Monoclonal Antitoxin Antibodies Actoxumab and Bezlotoxumab , 2014, Infection and Immunity.

[61]  D. Ho,et al.  A DNA vaccine targeting the receptor-binding domain of Clostridium difficile toxin A. , 2009, Vaccine.

[62]  V. Palda,et al.  Probiotics for the prevention of antibiotic-associated diarrhea and Clostridium difficile infection among hospitalized patients: systematic review and meta-analysis , 2013, Open medicine : a peer-reviewed, independent, open-access journal.

[63]  Jeffrey D Goldsmith,et al.  A mouse model of Clostridium difficile-associated disease. , 2008, Gastroenterology.

[64]  Mark H. Wilcox,et al.  Clostridium difficile infection: new developments in epidemiology and pathogenesis , 2009, Nature Reviews Microbiology.

[65]  S. Tzipori,et al.  Antibody against TcdB, but not TcdA, prevents development of gastrointestinal and systemic Clostridium difficile disease. , 2013, The Journal of infectious diseases.

[66]  R. Chinn,et al.  National point prevalence of Clostridium difficile in US health care facility inpatients, 2008. , 2009, American journal of infection control.

[67]  D. Schmidt,et al.  A novel multivalent, single-domain antibody targeting TcdA and TcdB prevents fulminant Clostridium difficile infection in mice. , 2014, The Journal of infectious diseases.

[68]  S. Gorbach.  Probiotics and gastrointestinal health. , 2000, The American journal of gastroenterology.

[69]  J. Tanha,et al.  Neutralization of Clostridium difficile Toxin A with Single-domain Antibodies Targeting the Cell Receptor Binding Domain* , 2011, The Journal of Biological Chemistry.

[70]  L. McDonald,et al.  Clostridium difficile-associated disease: new challenges from an established pathogen. , 2006, Cleveland Clinic journal of medicine.

[71]  C. Kelly,et al.  New Drugs and Strategies for Management of Clostridium difficile Colitis , 2014, Journal of intensive care medicine.

[72]  Robert B. Mandell,et al.  Human Monoclonal Antibodies Directed against Toxins A and B Prevent Clostridium difficile-Induced Mortality in Hamsters , 2006, Infection and Immunity.

[73]  J. Ballard,et al.  Clostridium difficile Toxins: Mechanism of Action and Role in Disease , 2005, Clinical Microbiology Reviews.

[74]  C. Shoemaker,et al.  Alpaca (Lama pacos) as a convenient source of recombinant camelid heavy chain antibodies (VHHs). , 2007, Journal of immunological methods.

[75]  J. Bartlett.  Narrative Review: The New Epidemic of Clostridium difficileAssociated Enteric Disease , 2006, Annals of Internal Medicine.

[76]  I. Lowy,et al.  Open-label, dose escalation phase I study in healthy volunteers to evaluate the safety and pharmacokinetics of a human monoclonal antibody to Clostridium difficile toxin A. , 2008, Vaccine.

[77]  E. Remaut,et al.  Orally administered L. lactis secreting an anti-TNF Nanobody demonstrate efficacy in chronic colitis , 2010, Mucosal Immunology.

[78]  Roger Baxter,et al.  Serum anti-toxin B antibody correlates with protection from recurrent Clostridium difficile infection (CDI). , 2010, Vaccine.